Literature DB >> 21739583

How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel.

Philip S Rosenberg1, Hannah Tamary, Blanche P Alter.   

Abstract

For many recessive genetic syndromes, carrier frequencies have been assessed through screening studies in founder populations but remain unclear in heterogeneous populations. One such syndrome is Fanconi Anemia (FA). FA is a model disease in cancer research, yet there are no contemporary data on carrier frequency or prevalence in the general United States (US) population or elsewhere. We inferred carrier frequency from birth incidence using the Hardy-Weinberg law. We estimated prevalence using birth incidence and survival data. We defined "plausible ranges" to incorporate uncertainty about completeness of case ascertainment. We made estimates for the US and Israel using demographic data from the Fanconi Anemia Research Fund and Israeli Fanconi Anemia Registry. In the US, a plausible range for the carrier frequency is 1:156-1:209 [midpoint 1:181]; we estimate that 550-975 persons were living with FA in 2010. For Israel, a plausible range for the carrier frequency is 1:66-1:128 [midpoint 1:93] in line with founder screening studies; we estimate that 40-135 Israelis were living with FA in 2008. The estimated US FA carrier frequency of 1:181 is significantly higher than the historical estimate of 1:300; hence, the gap may be narrower than previously recognized between the US carrier frequency and higher carrier frequencies of around 1:100 in several founder groups including Ashkenazi Jews. Assessment of cancer risks in heterozygous carriers merits further study. Clinical trials in FA will require co-ordination and innovative design because the number of living US patients is probably less than 1,000. This article is a US Government work and, as such, is in the public domain in the United States of America. Published 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21739583      PMCID: PMC3140593          DOI: 10.1002/ajmg.a.34087

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  42 in total

Review 1.  Heterozygous manifestations in four autosomal recessive human cancer-prone syndromes: ataxia telangiectasia, xeroderma pigmentosum, Fanconi anemia, and Bloom syndrome.

Authors:  R A Heim; N J Lench; M Swift
Journal:  Mutat Res       Date:  1992-12-01       Impact factor: 2.433

2.  Fanconi anemia: another disease of unusually high prevalence in the Afrikaans population of South Africa.

Authors:  J Rosendorff; R Bernstein; L Macdougall; T Jenkins
Journal:  Am J Med Genet       Date:  1987-08

3.  Fanconi's anaemia in the genetics of neoplasia.

Authors:  M Swift
Journal:  Nature       Date:  1971-04-09       Impact factor: 49.962

4.  The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population.

Authors:  M A Whitney; P Jakobs; M Kaback; R E Moses; M Grompe
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

5.  Fanconi anemia in black African children.

Authors:  L G Macdougall; M C Greeff; J Rosendorff; R Bernstein
Journal:  Am J Med Genet       Date:  1990-08

6.  Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory.

Authors:  Charles M Strom; Beryl Crossley; Joy B Redman; Franklin Quan; Arlene Buller; Matthew J McGinniss; Weimin Sun
Journal:  Genet Med       Date:  2004 May-Jun       Impact factor: 8.822

7.  Comparative study of Fanconi anemia in children of different ethnic origin in South Africa.

Authors:  L G Macdougall; J Rosendorff; J E Poole; R J Cohn; S E McElligott
Journal:  Am J Med Genet       Date:  1994-09-01

8.  Cancer in relatives of patients with aplastic anemia.

Authors:  N U Potter; C Sarmousakis; F P Li
Journal:  Cancer Genet Cytogenet       Date:  1983-05

9.  Reassessment of cancer predisposition of Fanconi anemia heterozygotes.

Authors:  M Swift; R J Caldwell; C Chase
Journal:  J Natl Cancer Inst       Date:  1980-11       Impact factor: 13.506

10.  Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study.

Authors:  A Butturini; R P Gale; P C Verlander; B Adler-Brecher; A P Gillio; A D Auerbach
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  47 in total

1.  Analysis of overlapping heterozygous novel submicroscopic CNVs and FANCA-VPS9D1 fusion transcripts in a Fanconi anemia patient.

Authors:  Daijing Nie; Panxiang Cao; Fang Wang; Jing Zhang; Mingyue Liu; Wei Zhang; Lili Liu; Huizheng Zhao; Wen Teng; Wenjun Tian; Xue Chen; Yang Zhang; Hua Nan; Zhijie Wei; Tong Wang; Hongxing Liu
Journal:  J Hum Genet       Date:  2019-06-26       Impact factor: 3.172

2.  Population Frequency of Fanconi Pathway Gene Variants and Their Association with Survival After Hematopoietic Cell Transplantation for Severe Aplastic Anemia.

Authors:  Lisa J McReynolds; Youjin Wang; Ashley S Thompson; Bari J Ballew; Jung Kim; Blanche P Alter; Belynda Hicks; Bin Zhu; Kristine Jones; Stephen R Spellman; Tao Wang; Stephanie J Lee; Sharon A Savage; Shahinaz M Gadalla
Journal:  Biol Blood Marrow Transplant       Date:  2020-01-23       Impact factor: 5.742

3.  Cytogenetic study is not essential in patients with aplastic anemia.

Authors:  Atreyee Dutta; Rajib De; Tuphan K Dolai; Pradip K Mitra; Ajanta Halder
Journal:  Am J Blood Res       Date:  2017-11-01

Review 4.  The Fanconi anemia ID2 complex: dueling saxes at the crossroads.

Authors:  Rebecca A Boisvert; Niall G Howlett
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Global and disease-associated genetic variation in the human Fanconi anemia gene family.

Authors:  Kai J Rogers; Wenqing Fu; Joshua M Akey; Raymond J Monnat
Journal:  Hum Mol Genet       Date:  2014-08-07       Impact factor: 6.150

Review 6.  Genetic counseling for Fanconi anemia: crosslinking disciplines.

Authors:  Heather A Zierhut; Rebecca Tryon; Erica M Sanborn
Journal:  J Genet Couns       Date:  2014-09-20       Impact factor: 2.537

Review 7.  Fanconi anaemia and the repair of Watson and Crick DNA crosslinks.

Authors:  Molly C Kottemann; Agata Smogorzewska
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

8.  Anti-Müllerian hormone deficiency in females with Fanconi anemia.

Authors:  Martha M Sklavos; Neelam Giri; Pamela Stratton; Blanche P Alter; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-01-17       Impact factor: 5.958

Review 9.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

Review 10.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma.

Authors:  Lindsey E Romick-Rosendale; Vivian W Y Lui; Jennifer R Grandis; Susanne I Wells
Journal:  Mutat Res       Date:  2013-01-17       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.